Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06276556 · ClinicalTrials.gov registry record · Phase 2
Extension Study of ABP-671 in Participants With Gout
A Phase 2 study, sponsored by Atom Therapeutics Co..
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT06276556 is a Phase 2 study that was terminated before completion, run by Atom Therapeutics Co.. The registered enrollment target is 43 participants.
The verdict
NCT06276556, a Phase 2 study, was terminated before completion, sponsored by Atom Therapeutics Co..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3).
Interventions
- DRUG Allopurinol
- DRUG ABP-671
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2024-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06276556
The ClinicalTrials.gov registry entry for NCT06276556 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atom Therapeutics Co., which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Allopurinol is the first listed.
NCT06276556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06276556 about?
NCT06276556 is a clinical study titled "Extension Study of ABP-671 in Participants With Gout". The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3)...
What is the current status of trial NCT06276556?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2024-04-22. Estimated completion is 2024-09-05.
What interventions are being tested in trial NCT06276556?
The interventions under investigation include: Allopurinol (DRUG), ABP-671 (DRUG).
Who is sponsoring clinical trial NCT06276556?
This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.